Galectin Therapeutics' NAVIGATE Data Validates Fibrosis Thesis

Galectin Therapeutics has presented data from its NAVIGATE study, validating the company's thesis on fibrosis. The study demonstrated the potential of galectin-3 inhibition as a treatment for fibrotic diseases. Galectin-3 is a protein involved in the development and progression of fibrosis. The data suggests that inhibiting galectin-3 could be a viable treatment strategy for fibrotic diseases. This is a significant development for Galectin Therapeutics and the broader biotech industry, as it provides a clear mechanistic rationale for the treatment of fibrosis.